A Stud Of Cardiovascular Screening In Lung Transplant Candidates

Overview

About this study

The purpose of this study is to determine prevalence of high and intermediate probability HFpEF in lung transplant candidates using the HF2PEF and HFpEF-ABA scoring tools

and correlate with invasive hemodynamic measurements when available (retrospective).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients who underwent lung transplant between 1/1/2014 and 12/31/2024 at Mayo Clinic in Florida

Exclusion Criteria:

  • Patients who underwent combined heart and lung transplant and those with EF <50%

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 04/06/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions